KalVista Pharmaceuticals, Inc. (KALV)

Market Cap	1.07B +86.2%
Revenue (ttm)	73.62M
Net Income	-164.29M
EPS	-3.05
Shares Out	51.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	889,379
Open	20.33
Previous Close	20.29
Day's Range	20.02 - 20.91
52-Week Range	9.83 - 21.31
Beta	-0.40
Analysts	Strong Buy
Price Target	32.60 (+56.28%)
Earnings Date	May 9, 2026

About KALV

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmace...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Benjamin Palleiko
• Employees: 275
• Stock Exchange: NASDAQ
• Ticker Symbol: KALV
• Website: https://www.kalvista.com

Analyst Summary

According to 5 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price target is $32.6, which is an increase of 56.28% from the latest price.

Price Target

$32.6

(56.28% upside)

Analyst Consensus: Strong Buy